سعر مالاري-كو 10 اقراص 2022

Malari-Co tablets (artemether + lumefantrine), 10 tablets, artemisinin-based combination antimalarial by Multi-Apex (Egypt); per-tablet strength not stated by the sources opened.

• Adults (> 30%): headache, anorexia, dizziness, asthenia, arthralgia and myalgia. Children (> 12%): pyrexia, cough, vomiting, anorexia and headache.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to artemether, lumefantrine or any excipient.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Co-administration with strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin and St John's wort (decreased artemether/lumefantrine concentrations and loss of antimalarial efficacy).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• QT prolongation: avoid in patients with congenital QT prolongation or conditions prolonging QTc (history of symptomatic arrhythmias, clinically relevant bradycardia, severe cardiac disease), a family history of congenital QT prolongation or sudden death, hypokalaemia or hypomagnesaemia, or taking other QT-prolonging drugs or CYP2D6 substrates with cardiac effects.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Halofantrine and artemether/lumefantrine should not be given within one month of each other (additive QT effects); other antimalarials should not be given concomitantly unless there is no other treatment option.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Take with food to improve absorption; patients who remain averse to food should be closely monitored as the risk of recrudescence may be greater; not approved for severe/complicated malaria or for prevention.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• CYP3A4 inhibitors and inducers, including antiretroviralsStrong CYP3A4 inducers are contraindicated (loss of efficacy). Ketoconazole, a potent CYP3A4 inhibitor, moderately increased artemether, DHA and lumefantrine exposure (no dose adjustment per US label, but caution with QT effects); antiretrovirals that inhibit or induce CYP3A4 may alter exposure - use with caution.DailyMed (U.S. National Library of Medicine)
• Hormonal contraceptivesArtemether/lumefantrine may reduce the effectiveness of hormonal contraceptives; patients should use an alternative non-hormonal method or add a barrier method during treatment.DailyMed (U.S. National Library of Medicine)
• CYP2D6 substrates (e.g. flecainide, imipramine, amitriptyline, clomipramine)Lumefantrine inhibits CYP2D6 and may increase levels of CYP2D6 substrates, particularly those with a narrow therapeutic index or QT-prolonging effect.DailyMed (U.S. National Library of Medicine)

English text not available for this section.